Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders

MISSISSAUGA, Ontario, June 16, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting (the "Meeting") of shareholders (the "Shareholders") held earlier today, which included the election of directors, as described below. 

The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represented by proxy at the Meeting was an aggregate of 49,371,169, representing 77.12% of the Company's issued and outstanding Common Shares.

According to proxies received and a vote by ballot, the voting results in respect of each of the following eight director nominees, all of whom previously served as directors of the Company, were as follows:

Nominee

Number of Shares

Percentage of Votes Cast
(approximate)


Votes For:

Votes
Withheld:

Votes For:

Votes
Withheld:

Arthur S. Kirsch (Chairman)

36,864,255

701,174

98.13%

1.87%

Adrian Adams

36,924,816

640,613

98.29%

1.71%

Jason M. Aryeh

34,724,222

2,841,207

92.44%

7.56%

Neal F. Fowler

34,912,811

2,652,618

92.94%

7.06%

Rob Harris

36,728,124

837,305

97.77%

2.23%

Kenneth B. Lee, Jr.

34,432,470

3,132,959

91.66%

8.34%

Seth A. Rudnick, M.D.

34,916,599

2,648,830

92.95%

7.05%

F. Martin Thrasher

37,299,273

266,156

99.29%

0.71%

Each of the other matters put forward before Shareholders for consideration and approval at the Meeting, as described in the Company's proxy statement dated May 6, 2016, was duly approved by the requisite number of votes.

Final voting results of all other matters voted on at the Meeting will be made available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.

About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.

Aralez Pharmaceuticals US Inc. Contact:
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com

SOURCE Aralez Pharmaceuticals Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890